Shifting paradigms in the systemic management of hepatocellular carcinoma

Lancet Gastroenterol Hepatol. 2020 Oct;5(10):883-885. doi: 10.1016/S2468-1253(20)30250-8.

Author

David J Pinato¹

Affiliation

¹ Department of Surgery and Cancer, Imperial College London, Faculty of Medicine, Hammersmith Hospital, London W12 0NN, UK. Electronic address: david.pinato@imperial.ac.uk.

PMID: 32941832
DOI: 10.1016/S2468-1253(20)30250-8

No abstract available

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Antibodies, Monoclonal, Humanized / therapeutic use
Antineoplastic Agents, Immunological / therapeutic use
Bevacizumab / therapeutic use
Carcinoma, Hepatocellular / mortality
Carcinoma, Hepatocellular / therapy*
Cytotoxins / therapeutic use
Drug Therapy, Combination
Humans
Immunotherapy / methods*
Liver Neoplasms / epidemiology
Liver Neoplasms / pathology*
Precision Medicine / methods*
Protein Kinase Inhibitors / therapeutic use
Sorafenib / therapeutic use

Substances

Antibodies, Monoclonal, Humanized
Antineoplastic Agents, Immunological
Cytotoxins
Protein Kinase Inhibitors
Bevacizumab
atezolizumab
Sorafenib